Computational Modelling in Studies for Hepatitis C Virus (HCV) NS3 Protease

Author(s): Azat Mukhametov

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 12 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Hepatitis C virus (HCV) infected up to 3% of global human population. More than 350 thousand die annually due to liver cirrhosis and hepatocellular carcinoma, developed at the late stages of the disease. The typical ways of HCV transmission are: transfusion of contaminated blood and blood products; sharing syringes among intravenous drug users; use of poorly sterilized medical instruments in certain countries with bad sterilization practice. HCV is hard to identify, at early stages the disease is asymptomatic and progresses slowly. HCV RNA genome is highly variable, and thus interferes developing of a vaccine. HCV NS3 protease has received close attention as the promising drug target. Recent approval of Boceprevir and Telaprevir, the first inhibitors of HCV NS3 protease, has let increase effectiveness of anti-HCV therapy. Though these new medicines show drawbacks in drug resistance and genotype coverage, second and third generation of HCV protease inhibitors will overcome them. Computational modelling had an impact role in these discoveries. Involvement of modelling in studies for Hepatitis C (HCV) NS3 protease is considered in this review.

Keywords: Hepatitis C, HCV, NS3/4A protease, molecular modelling, computational chemistry.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 03 March, 2016
Page: [1351 - 1361]
Pages: 11
DOI: 10.2174/1568026616666151120112141
Price: $65

Article Metrics

PDF: 43
PRC: 1